Active	Status	Sponsor type	Region	Phase	Filter
4 Active 3 Inactive 7 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Reynolds, Michele
NCT06015282: The Celljuvant Study: a Phase 3 Immunogenicity and Safety Study of AQIVc Vaccine in Adults Aged 50 Years and Older	Active, not recruiting	3	7741	Europe, Canada, US, RoW	Investigational aQIVc, licensed QIV1, licensed QIV2	Seqirus	Influenza, Human	03/24	01/25
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)	Recruiting	3	12500	Europe, Canada, Japan, US, RoW	Lepodisiran Sodium, LY3819469, Placebo	Eli Lilly and Company	Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)	03/29	03/29
ATTAIN-1, NCT05869903: A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities	Active, not recruiting	3	3000	Europe, Japan, US, RoW	Orforglipron, LY3502970, Placebo	Eli Lilly and Company	Obesity, Overweight, Overweight or Obesity	07/25	07/27
NCT04505436: Study to Evaluate Efficacy, Safety and Tolerability of HM15211 in Subjects	Recruiting	2	240	US, RoW	HM15211, Placebo of HM15211	Hanmi Pharmaceutical Company Limited	NASH - Nonalcoholic Steatohepatitis	05/25	11/25